MARKET

ACRX

ACRX

Acelrx Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.770
-0.120
-6.35%
After Hours: 1.780 +0.01 +0.57% 17:55 10/19 EDT
OPEN
1.910
PREV CLOSE
1.890
HIGH
1.920
LOW
1.730
VOLUME
1.76M
TURNOVER
--
52 WEEK HIGH
2.500
52 WEEK LOW
0.7014
MARKET CAP
159.87M
P/E (TTM)
-2.8443
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
RedHill's (RDHL) RHB-204 Gets FDA Orphan Drug Designation
RedHill (RDHL) gets Orphan Drug status from the FDA for the treatment of nontuberculous mycobacteria (NTM) disease.
Zacks · 4d ago
AcelRx Pharmaceuticals (ACRX) Upgraded to Buy: Here's Why
AcelRx Pharmaceuticals (ACRX) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks · 6d ago
AcelRx (ACRX) Looks Good: Stock Adds 5.3% in Session
AcelRx (ACRX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Zacks · 6d ago
Is the Options Market Predicting a Spike in AcelRx (ACRX) Stock?
Investors need to pay close attention to AcelRx (ACRX) stock based on the movements in the options market lately.
Zacks · 10/12 13:59
TWLO, ACRX among premarket gainers
Lizhi (LIZI) +46%. as Government picks Lizhi its backed pilot program to bolster local online audiovisual industry.Acorn (ATV) +31% on revised going private transaction for $21/share.LMP Automotive (LMPX) +21%. to acquire 70% interest in
Seekingalpha · 10/12 12:33
PGEN, ACRX, MNK and FTV among midday movers
Gainers: Sanchez Midstream Partners (SNMP) +124%.VivoPower International (VVPR) +92%.SpartanNash (SPTN) +34%.Precigen (PGEN) +29%.India Globalization Capital (IGC) +26%.Marine Petroleum Trust (MARPS) +25%.Just Energy (JE) +23%.cbdMD (YCBD) +22%.Medigus (MDGS) +21%.AcelRx Pharmaceuticals (ACRX) +17%.Losers: ShiftPixy (PIXY) -25%.Camber Energy
Seekingalpha · 10/09 16:38
AcelRx Pharmaceuticals Says On Oct. 1 Entered Promotion Agreement With La Jolla Pharmaceutical Company Pursuant To Which Co.s Restructured Co-Promotion Arrangement To Promote DSUVIA
On October 1, 2020, AcelRx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into a Promotion Agreement (the “Promotion Agreement”) with La Jolla Pharmaceutical Company, a
Benzinga · 10/06 20:17
AcelRx to Host Virtual KOL Event on Perioperative Use of DSUVIA®
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced it will host a virtual Key Opinion Leader (KOL) event on the perioperative use of
PR Newswire · 09/29 13:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ACRX. Analyze the recent business situations of Acelrx Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ACRX stock price target is 4.968 with a high estimate of 9.00 and a low estimate of 0.8400.
EPS
Institutional Holdings
Institutions: 104
Institutional Holdings: 18.82M
% Owned: 20.84%
Shares Outstanding: 90.32M
TypeInstitutionsShares
Increased
18
1.02M
New
21
331.22K
Decreased
22
2.45M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.82%
Pharmaceuticals & Medical Research
-1.70%
Key Executives
Chairman/Independent Director
Adrian Adams
Chief Executive Officer/Director
Vincent Angotti
Co-Founder/Director
Pamela Palmer
Chief Financial Officer
Raffi Asadorian
Other
Badri Dasu
Independent Director
Richard Afable
Independent Director
Mark Edwards
Independent Director
Stephen Hoffman
Independent Director
Howard Rosen
Independent Director
Mark Wan
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ACRX
AcelRx Pharmaceuticals, Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidates include DSUVIA (known as DZUVEO in Europe) and Zalviso. Its DSUVIA is indicated for use in adults in a certified medically supervised healthcare setting, such as hospitals, surgical centers, and emergency departments, for the management of acute pain. DSUVIA is designed to provide rapid analgesia via a non-invasive route and to eliminate dosing errors associated with IV administration. Its Zalviso is a sufentanil sublingual tablet system intended for the management of moderate-to-severe acute pain in hospitalized adult patients. Zalviso consists of a pre-filled cartridge of 40 sufentanil sublingual tablets, 15 microgram (McG), delivered by the Zalviso System, a needle-free, handheld, patient-administered, pain management system.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of AcelRx Pharmaceuticals Inc stock information, including NASDAQ:ACRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACRX stock methods without spending real money on the virtual paper trading platform.